Policy and its (failed) implementation

Jodi Wishnia February 2017   South Africa, like many middle income countries, has robust and technically sound policies but struggles with their implementation. In my opinion, the first step to understanding how the Life Esidimeni crisis and many other similar incidents happened, is to understand the disjuncture between policy and its implementation. Using the Life […]

Read More..

Bad Apples and a Just Culture

Gary Kantor February 2017 It’s tempting to conclude that MEC Mahlangu, Dr Selebano and Dr Manamela are the sole culprits in this distressing affair. After all, to quote Professor Makgoba, their “fingerprints” are “peppered throughout the project”.  This would be comforting, for if we simply get rid of the culprits – those who are to […]

Read More..

Industry Update: Demarcation Update

1.  Introduction This document has been prepared by Insight Actuaries and Consultants (Insight). The document outlines the key points of the demarcation agreement between medical schemes and health insurance offerings. The document also includes a brief history on demarcation. 2.  Regulation Definitions Health insurance benefits are usually stipulated as a cash sum that is either […]

Read More..

Round one of the HMI: Interpreting X-rays

Shivani Ranchod 11 March 2016   The first round of public hearings for the Competition Commission Health Market Inquiry (HMI) wrap up today. For those of us who have been obsessively following the proceedings it will be a relief to have a break before the next round. As one commentator tweeted: “Spellbound”. It has been […]

Read More..

Truvada: holy grail or poisoned chalice?

Guest post by Leigh Johnson On Tuesday, 8 December 2015, South Africa’s Medicines Control Council approved the use of Truvada for HIV prevention. Truvada, a combination of two antiretroviral agents, has been shown to be effective in preventing acquisition of HIV in people who take the drug regularly. It is one of two drugs commonly […]

Read More..

Low Cost Benefit Options: Doomed from the beginning?

Andre Bellingan The medical schemes industry was taken aback when the Council for Medical Schemes retracted its framework for Low Cover Benefit Options (LCBOs) on 12 October 2015, barely a month after it had been published at the end of a consultative process.  It appears that this retraction was at the behest of the National […]

Read More..

The lights go out one by one

Shivani Ranchod I have an uncle in his seventies who says that ageing hasn’t been too bad. Luckily, he says, the lights go out one by one. What he means is that your capacity diminishes slowly – giving you time to adjust to each loss. It seems that I have been reading and thinking about […]

Read More..

Transformation is not (just) an agenda item

Shivani Ranchod More than twenty years into South Africa’s democracy and we still struggle with what the notion of “transformation” means (never mind how to actually achieve transformation, a struggle on an entirely different scale). It is not entirely surprising given the nebulous and deeply personal nature of the issue. My understanding of transformation comes […]

Read More..

Conflict Or Collaboration

Conflict or collaboration – a choice that faces all stakeholders in the healthcare industry. In a sense, the BHF is one area of collaboration that already exists in the healthcare funding industry. To be sure there are many areas for potential conflict. There is a scarcity of resources in healthcare, and so market participants compete […]

Read More..

Benefit Design

At the recent BHF conference we had an opportunity to talk about benefit design – an area that is top of mind for schemes at the moment as 2016 pricing is finalised and preparations are underway to take 2016 products to the market. During this time of year benefit design can feel like just a […]

Read More..